Journal
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
Volume 159, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.ejps.2020.105691
Keywords
Supersaturated lipid-based drug delivery systems; Precipitation inhibitors; High throughput screening; Bio-enabling formulations; Pharmacokinetic profiles
Categories
Funding
- Horizon 2020 Marie Sklodowska-Curie Innovative Training Networks programme [674909]
Ask authors/readers for more resources
The study explores the use of precipitation inhibitors in supersaturated lipid-based drug delivery systems to enhance the bioavailability of cinnarizine. Results showed that inclusion of precipitation inhibitors led to increased cinnarizine bioavailability, particularly in certain formulations. By mitigating the risk of in vivo precipitation of cinnarizine, precipitation inhibitors allow for comparable bioavailability to non-supersaturated lipid systems.
Supersaturated lipid-based drug delivery systems are increasingly being explored as a bio-enabling formulation approach, particularly in preclinical evaluation of poorlywater-soluble drugs. While increasing the drug load through thermally-induced supersaturation resulted in enhanced in vivo exposure for some drugs, for others, such as cinnarizine, supersaturated lipid-based systems have not been found beneficial to increase the in vivo bioavailability. We hypothesized that incorporation of precipitation inhibitors to reduce drug precipitation may address this limitation. Therefore, pharmacokinetic profiles of cinnarizine supersaturated lipid-based drug delivery systems with or without precipitation inhibitors were compared. Five precipitation inhibitors were selected for investigation based on a high throughput screening of twenty-one excipients. In vivo results showed that addition of 5% precipitation inhibitors to long chain monoglyceride (LCM) or medium chain monoglyceride (MCM) formulations showed a general trend of increases in cinnarizine bioavailability, albeit only statistically significantly increased for Poloxamer 407 + LCM system (i.e. 2.7-fold increase in AUC(0-24h) compared to LCM without precipitation inhibitors). It appeared that precipitation inhibitors mitigated the risk of in vivo precipitation of cinnarizine from sLBDDS and overall, bioavailability was comparable to that previously reported for cinnarizine after dosing of non-supersaturated lipid systems. In summary, for drugs which are prone to precipitation from supersaturated lipid-based drug delivery systems, such as cinnarizine, inclusion of precipitation inhibitors mitigates this risk and provides the opportunity to maximize exposure which is ideally suited in early efficacy and toxicology evaluation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available